This is an article the I would trot out if anyone tried to argue that a Data Safety and Monitoring Board should, like the investigators, be blinded as to treatment status during their deliberations.

BRADLEY D. FREEMAN, ROBERT L. DANNER, STEVEN M. BANKS, and CHARLES NATANSON “Safeguarding Patients in Clinical Trials with High Mortality Rates”, American Journal of Respiratory and Critical Care Medicine, Vol. 164, No. 2 (2001), pp. 190-192. doi: 10.1164/ajrccm.164.2.2011028. Available at

This Blog post was added to the website on 2015-12-02 and was last modified on 2020-02-29. You can find similar pages at Blinding in research, Early stopping, Ethics in research.

An earlier version of this page appears here.